Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis

Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis

(2021) Yupeng Wang et al.   Multiple Sclerosis and Related Disorders

Myelin-oligodendrocyte glycoprotein antibody-associated disease

(2021) Romain Marignier et al.   LANCET NEUROLOGY

Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders

(2021) Elia Sechi et al.   NEUROLOGY

Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis

(2021) Cong Zhao et al.   Frontiers in Neurology

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation

(2020) Julia Loos et al.   JOURNAL OF NEUROLOGY

Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study

(2020) Yoshiki Takai et al.   BRAIN

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

(2020) Masayuki Tahara et al.   LANCET NEUROLOGY

Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis

(2020) Gaurav Nepal et al.   ACTA NEUROLOGICA SCANDINAVICA

Treatment of MOG antibody associated disorders: results of an international survey

(2020) D. H. Whittam et al.   JOURNAL OF NEUROLOGY

Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK

(2020) Karen O'Connell et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

(2020) John J. Chen et al.   NEUROLOGY

Serious safety events in rituximab‐treated multiple sclerosis and related disorders

(2020) Brandi L. Vollmer et al.   Annals of Clinical and Translational Neurology

Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey

(2020) Berin Inan et al.   Multiple Sclerosis and Related Disorders

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

(2020) Daniel H Whittam et al.   Multiple Sclerosis and Related Disorders

Effectiveness of rituximab in neuromyelitis optica: a meta-analysis

(2019) Fulin Gao et al.   BMC Neurology

The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults

(2019) CL de Mol et al.   Multiple Sclerosis Journal

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

(2019) Alvaro Cobo-Calvo et al.   Journal of Neuroinflammation

Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease

(2019) Fahad Albassam et al.   DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases

(2019) Pierre Durozard et al.   ANNALS OF NEUROLOGY

Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Optic Neuritis

(2018) Ilijas Jelcic et al.   JOURNAL OF NEURO-OPHTHALMOLOGY

Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders

(2018) A. Sebastian López-Chiriboga et al.   JAMA Neurology

Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

(2018) Yael Hacohen et al.   JAMA Neurology

MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder

(2018) Giordani Rodrigues dos Passos et al.   Frontiers in Neurology

Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis

(2018) Nadja Borisow et al.   Frontiers in Neurology

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

(2017) Sudarshini Ramanathan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders

(2016) Valentina Damato et al.   JAMA Neurology

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

(2015) Dean M. Wingerchuk et al.   NEUROLOGY

The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?

(2012) De-Hyung Lee et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

(2009) Alessandro Liberati et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY